Maraba virus as a potent oncolytic vaccine vector. - Test2 - elhamkhani - TriplyDB

Maraba virus as a potent oncolytic vaccine vector.

Maraba virus as a potent oncolytic vaccine vector.

http://www.wikidata.org/entity/Q37562080

about

Oncolytic Viruses: Therapeutics With an Identity Crisis Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch-Oncolytic viruses and cancer therapy Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Classification of current anticancer immunotherapies Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Reovirus in cancer therapy: an evidence-based review Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.Fighting Cancer with Mathematics and Viruses.Oncolytic viruses-immunotherapeutics on the rise.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Viral vanguard: Designing cancer-killing viruses to chase metastatic tumors.4th European Seminars in Virology on Oncogenic and Oncolytic Viruses, in Bertinoro (Bologna), Italy.S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.The Oncolytic Virus MG1 Targets and Eliminates Cells Latently Infected With HIV-1: Implications for an HIV Cure.Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Designing and building oncolytic viruses.Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.Trial watch: DNA-based vaccines for oncological indications Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital Microscopy Use of Precision-Cut Lung Slices as an Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic Therapy Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity Oncolytic virus and PD-1/PD-L1 blockade combination therapy The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

P2860

Q26741020-88EAB722-30F8-40B7-9D8A-5F497EFA95BA Q26767209-7725793B-63FD-4F61-8EA1-3D59F272CFB2 Q26774345-60C65CBE-BE0C-445B-B283-2FA178A00AFE Q26801501-8011247A-5AEE-4874-A6F7-8C523ACD6BFF Q27021951-982506EC-4879-4E8D-BCD1-18DD53AF1D67 Q28072347-183E0B67-5753-44AB-B19A-C5D1014EED03 Q33551626-1635681D-FC07-49F3-88EF-66A83E3B1FF3 Q35149637-F0A59004-826E-444F-8D07-4152D76085CB Q36664229-25163C96-4D46-4D44-8304-F94843097B0D Q37031909-7DE7388F-7CF6-4605-A9E8-7448523006BB Q37417618-BEF326F8-3B34-4881-A812-1594C2DA437F Q38243811-9650EE19-44E3-4297-8128-1F47D3F4DFDF Q38612646-68A54434-DC3A-43EA-BD30-0BB589C93AB0 Q38919107-7FE06A82-E90F-4A0E-8D0F-474556569690 Q39387174-DAA4DB02-0DFF-4407-9798-CF7B219406D3 Q39437344-1C54180F-A9D4-448D-861C-CB3C7EB9B358 Q39763165-FD12761F-CE1C-4F2B-B41A-AD63AA5BD1F6 Q40104793-F9477550-6F58-45E9-95EF-45FB82452511 Q40171064-349DB3F5-064F-4A95-957C-2F7EFCAAF15E Q40470227-F6E21E92-F0EB-4630-B98B-E2CC7D0BAE13 Q40729421-05118537-3B3E-43E7-855C-75D51114BDC9 Q41137180-3A2F27D7-6AA1-41C3-94C5-7447F2D9D64F Q42795549-91378297-DADD-43A1-8079-3DB944C1D5C8 Q45323510-266FE06F-E7DE-4F25-A153-4886D9822FC9 Q45323818-59F42FB4-32E1-4457-BBC1-43DE465A290F Q45324726-3E70A739-FACC-4D67-93B7-4E11FD434F97 Q45324769-98F80279-9481-47A7-8093-D451F7A1D61A Q47547386-BB1EA467-44F2-4C1E-8CEF-82852A2665BF Q47559036-9B96C482-44EB-455D-A040-0A04A9AC57F6 Q49715030-EA1CB454-35CF-4CFA-8F7B-8DF957010CBF Q50865520-7A4A2350-C167-4381-B595-A5F356BE62B3 Q54218762-208B26B7-F867-477D-B45E-D5134A49D958 Q55085319-A1C005B8-D523-4732-9522-6094510D2994 Q55509278-222E7748-211C-457D-9EBC-097CF054D210 Q56893452-6E7BCB19-FCF7-45CF-AB53-E2292D67E976 Q56991805-49891C64-325E-43D8-97C0-70EFC0CF82AD Q57020780-993253DD-541E-42D9-ACED-B63B7740A100 Q57161784-313201D9-D596-4818-9EFF-85D9150E8714 Q57174025-7A666106-F69F-496A-9708-57D78BD8CCAD Q58750585-68D59CDB-A17D-4E16-A89A-7BDADED1B0BC

P2860

Maraba virus as a potent oncolytic vaccine vector.

http://www.wikidata.org/entity/Q37562080

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Maraba virus as a potent oncolytic vaccine vector.

@en

Maraba virus as a potent oncolytic vaccine vector.

@nl

type

label

Maraba virus as a potent oncolytic vaccine vector.

@en

Maraba virus as a potent oncolytic vaccine vector.

@nl

prefLabel

Maraba virus as a potent oncolytic vaccine vector.

@en

Maraba virus as a potent oncolytic vaccine vector.

@nl

P1433

Q37562080-31964391-D9CB-4FC7-BFAA-44361A6E41E2

P1476

Q37562080-FFB95F18-A208-4369-B14A-AD939D6CFA4A

P2093

Q37562080-0469E0BC-4402-429F-924E-821709217B8A

Q37562080-2215FBCA-E8E4-4375-AFA4-F9649BD0CE72

Q37562080-248C4ECA-1871-453F-B85A-09346BEE7A3E

Q37562080-289399C2-80A6-4736-928A-C5A0EF0AC838

Q37562080-60D82CEA-9BAE-4434-880A-A78470D51175

Q37562080-69852764-F8BC-4C13-971E-F7DA9305C5D2

Q37562080-91A856A6-6530-4283-A179-DDB614392F6A

Q37562080-A6D0070A-3FE2-44F1-AB59-CFBCE7247BA7

Q37562080-E0C1EEE0-902E-4C25-AA4D-3D5C4143D8F6

Q37562080-FFD91CA2-5418-4E7B-A13F-A561BB5333F1

P2860

Q37562080-09E7089C-36E6-4D3E-923A-AA3F5D2A5856

Q37562080-25D7B10A-F7F3-4665-A012-A86BD2460141

Q37562080-2A6E6EA7-68DB-4C5A-B3B4-0DBFF84C73F9

Q37562080-37EB352D-6BDC-449C-9F63-4EF84138571F

Q37562080-4120977B-8582-41FD-ABCB-48338F66D71D

Q37562080-45E639AF-BADE-4EAE-A307-E9D77F0BE80D

Q37562080-540BE0AC-BA96-452C-87F4-015C7665645A

Q37562080-579DEB8D-D700-4631-A3B4-3602997D6E5D

Q37562080-57F915F3-A9CA-40A2-A914-67C0AED75039

Q37562080-5BFA4C86-E274-447F-90BA-853B2F0CB990

P304

Q37562080-51D4488B-1D2F-4D88-83EE-4EA659C8133A

P31

Q37562080-E571C6AB-CFFC-4FAB-B6F2-FDD473FCAEC7

P356

Q37562080-B35B6A8A-DB2B-4A3F-9E85-6921B8F196B6

P433

Q37562080-8B337732-E80D-4F9F-A155-88224725CC88

P478

Q37562080-5167B2A4-29B8-41C7-B197-05C007056BF0

P50

Q37562080-2E19CF1F-6A2A-404E-A4EE-3C19B10B5CA2

Q37562080-E1CFA609-0462-4381-8F97-25F17E219107

P577

Q37562080-DFC74521-72EA-42A0-B7D1-FA14A28488F2

P5875

Q37562080-B063A92C-3E28-4FAC-A3F7-1ED7355C4135

P698

Q37562080-3A4EA6B4-42A4-4038-BBB7-90E4B2C42156

P921

Q37562080-4BF49FD7-A0C6-4304-8719-2D821AEEF861

Q37562080-8A317190-53CF-4280-9AFC-B347DFB8CDAE

P932

Q37562080-0235A173-DD8D-45E6-97BA-FDD3E42DC811

P356

P1433

Molecular Therapy

P1476

Maraba virus as a potent oncolytic vaccine vector.

@en

P2093

Brian D Lichty

http://www.w3.org/2001/XMLSchema#string

Byram W Bridle

http://www.w3.org/2001/XMLSchema#string

David F Stojdl

http://www.w3.org/2001/XMLSchema#string

Julien Rességuier

http://www.w3.org/2001/XMLSchema#string

Kyle B Stephenson

http://www.w3.org/2001/XMLSchema#string

Lan Chen

http://www.w3.org/2001/XMLSchema#string

Liang Zhang

http://www.w3.org/2001/XMLSchema#string

Natasha Kazdhan

http://www.w3.org/2001/XMLSchema#string

Stephen Hanson

http://www.w3.org/2001/XMLSchema#string

Yonghong Wan

http://www.w3.org/2001/XMLSchema#string

P2860

Thunder and lightning: immunotherapy and oncolytic viruses collide

Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA

Targeting tumor vasculature with an oncolytic virus.

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

Recombinant vesicular stomatitis viruses from DNA.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

P304

420-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2013.249

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan L Bramson

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259252293

http://www.w3.org/2001/XMLSchema#string

P698

24322333

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

vector-borne disease

P932

3916044

http://www.w3.org/2001/XMLSchema#string